Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Bridge to Life
AddedFeb 15, 2024
UpdatedJun 18, 2026
Bridge to Life

Bridge to Life

Bridge to Life: Global supplier of innovative organ preservation and machine perfusion solutions.

HQ
Northbrook, IL, US
Founded
2005
Overview
Compare
Fundraising
Employees
Website

Bridge to Life was founded with the core mission of advancing organ preservation and transplantation through innovative solutions. The company offers a range of products including the Belzer UW® Cold Storage Solution, Belzer MPS® UW Machine Perfusion Solution, EasiSlush® Sodium Chloride Solution for Slush Preparation, and the VitaSmart™ Machine Perfusion System. Their market focus is on providing cutting-edge preservation solutions to healthcare providers globally, aiming to improve the outcomes of organ transplants.

Notable affiliated people include experts in the field of organ transplantation and preservation, although specific names are not provided. Key achievements include the development and global distribution of their flagship products, which have become essential tools in organ preservation. Bridge to Life's impact is significant in the medical community, contributing to enhanced transplant success rates and better patient outcomes worldwide.

Bridge to Life - Similar Companies

BioLife Solutions logo

BioLife Solutions

BiomedInnovations logo

BiomedInnovations

Vascular Perfusion Solutions logo

Vascular Perfusion Solutions

Paragonix Technologies logo

Paragonix Technologies

TransMedics logo

TransMedics

transmedics.com

LifeBridge Innovations logo

LifeBridge Innovations

OmniLife logo

OmniLife

getomnilife.com

BMI OrganBank logo

BMI OrganBank

bmiorganbank.com

Ezalife logo

Ezalife

ezalife.com

Bridge Medicines logo

Bridge Medicines

Breath of Life logo

Breath of Life

Life-Assist logo

Life-Assist

LifeSprout logo

LifeSprout

lifesproutbio.com

Bridge Therapeutics logo

Bridge Therapeutics

Oxygen4Life logo

Oxygen4Life

oxygen4life.com

Bridge to Life - Quick Facts

Who are Bridge to Life's competitors?

Companies similar to Bridge to Life include BioLife Solutions, BiomedInnovations, Vascular Perfusion Solutions and Paragonix Technologies.

When was Bridge to Life founded?

Bridge to Life was founded in 2005.

Where is Bridge to Life's headquarters located?

Bridge to Life's headquarters is located in Northbrook, IL, US.

When was Bridge to Life's last funding round?

Bridge to Life's most recent funding round was for $56M (USD) in August 2021.

How much has Bridge to Life raised to-date?

As of Aug 19, 2021, Bridge to Life has raised a total of $56M (USD).

How many employees does Bridge to Life have?

Bridge to Life has 175 employees as of Feb 4, 2024.

Bridge to Life - Classification

Industry
  • Hardware
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
  • Transactional
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7372Prepackaged Software